Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients

NEXT STORY
Phoenix Life Sciences International Announces Giving Pledge Commitment and Launch of The Global Health Initiative with Kylie OBrien Ph.D.
PREV STORY
Teladoc Health to Develop First Pediatric-Specific Consumer Telehealth Platform with Cincinnati Children’s
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

HealthLynked Corp. Creates Data Archive with over 15,000 Medical Articles Covering a Wide Range of Medical Topics for Use in its AI Architecture

NAPLES, Fla., Sept. 04, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced ...

author_avatar
NASDAQ Market News

Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients

author_avatar
NASDAQ Market News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

author_avatar
NASDAQ Market News